The main purpose of this study is to find out how many people in Spain have been diagnosed with narcolepsy type 1 and type 2, and how many new participants are diagnosed each year. Narcolepsy is a rare sleep disorder that causes excessive daytime sleepiness. The researchers will look at medical records from hospitals across Spain to count participants with these conditions and understand patterns in diagnosis over time.
The aim is to do epidemiology study in the core group thus the enrolment number is not applicable to this group, however approximately100 participants in the supplementary group (online survey).
Study Type
OBSERVATIONAL
Enrollment
100
As this is an observational study, no intervention will be administered.
Core Group: Prevalence of Participants With NT1 and NT2 per 100,000 Population
The overall study prevalence will be calculated as the number of participants diagnosed with NT1 and NT2 from all public hospitals reporting cases divided by number of people living in the areas served by these hospitals resulting in a study prevalence fraction. The study prevalence fraction will be then extrapolated to the Spanish population to estimate the standardized overall prevalence of NT1 and NT2 in Spain.
Time frame: Up to 1 year
Core Group: Prevalence of Adult Participants With NT1 and NT2 per 100,000 Adult Population
The overall study prevalence will be calculated as the number of adult participants diagnosed with NT1 and NT2 from all public hospitals reporting cases divided by number of adult people living in the areas served by these hospitals resulting in a study prevalence fraction. The study prevalence fraction will be then extrapolated to the Spanish population to estimate the standardized overall prevalence of NT1 and NT2 in Spain.
Time frame: Up to 1 year
Core Group: Prevalence of Paediatric/Adolescent Participants With NT1 and NT2 per 100,000 Paediatric/Adolescent Population
The overall study prevalence will be calculated as number of diagnosed paediatric/adolescent participants from all public hospitals divided by number of paediatric/adolescent living in the areas served by these hospitals resulting in a study prevalence fraction. The study prevalence fraction will be then extrapolated to the Spanish population to estimate the standardized overall prevalence of NT1 and NT2 in Spain.
Time frame: Up to 1 year
Core Group: Prevalence of Male Participants With NT1 and NT2 per 100,000 Male Population
The overall study prevalence will be calculated as the number of male participants diagnosed with NT1 and NT2 from all public hospitals reporting cases divided by number of males living in the areas served by these hospitals resulting in a study prevalence fraction. The study prevalence fraction will be then extrapolated to the Spanish population to estimate the standardized overall prevalence of NT1 and NT2 in Spain.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Up to 1 year
Core Group: Prevalence of Female Participants With NT1 and NT2 per 100,000 Females Population
The overall study prevalence will be calculated as the number of female participants diagnosed with NT1 and NT2 from all public hospitals reporting cases divided by number of females living in the areas served by these hospitals resulting in a study prevalence fraction. The study prevalence fraction will be then extrapolated to the Spanish population to estimate the standardized overall prevalence of NT1 and NT2 in Spain.
Time frame: Up to 1 year
Core Group: Incidence of NT1 and NT2 per 100,000 Population
The incidence for both the years will be calculated as (average of both years). And for each year, the number of participants diagnosed for the first time from all hospitals divided by number of people living in the areas served by the hospitals resulting in a study incidence fraction. The study incidence fraction will be then extrapolated to the Spanish population to estimate the standardized overall incidence of NT1 and NT2 in Spain.
Time frame: Up to 2 years
Core Group: Incidence of NT1 and NT2 per 100,000 Adult Population
The incidence for both the years will be calculated as (average of both years) and for each year, the number of adult participants diagnosed for the first time from all hospitals divided by number of adults living in the areas served by these hospitals resulting in a study incidence fraction. The study incidence fraction will be then extrapolated to the Spanish population to estimate the standardized overall incidence of NT1 and NT2 in Spain.
Time frame: Up to 2 years
Core Group: Incidence of Paediatric/Adolescent NT1 and NT2 per 100,000 Paediatric/Adolescent Population
The incidence for both the years will be calculated as (average of both years) and for each year, the number of paediatric/adolescent participants diagnosed for the first time from all hospitals divided by number of paediatric/adolescent living in the areas served by these hospitals resulting in a study incidence fraction. The study incidence fraction will be then extrapolated to the Spanish population to estimate the standardized overall incidence of NT1 and NT2 in Spain.
Time frame: Up to 2 years
Core Group: Incidence of Male NT1 and NT2 per 100,000 Male Population
The incidence for both the years will be calculated as (average of both years) and for each year, the number of male participants diagnosed for the first time from all hospitals divided by number of male participants living in the areas served by these hospitals resulting in a study incidence fraction. The study incidence fraction will be then extrapolated to the Spanish population to estimate the standardized overall incidence of NT1 and NT2 in Spain.
Time frame: Up to 2 years
Core Group: Incidence of Female NT1 and NT2 per 100,000 Female Population
The incidence for both the years will be calculated as (average of both years) and for each year, the number of female participants diagnosed for the first time from all hospitals divided by number of female participants living in the areas served by these hospitals resulting in a study incidence fraction. The study incidence fraction will be then extrapolated to the Spanish population to estimate the standardized overall incidence of NT1 and NT2 in Spain.
Time frame: Up to 2 years
Supplementary Group: Number of Participants with NT1 and NT2 who Attend Regular Follow-ups
Proportion of Participants with NT1 and NT2 in Spain who attended regular follow ups at only public hospitals, only private hospitals, and both private and public hospitals will be reported.
Time frame: On a day of survey (any 1 day) during the study for each participant
Core Group: Proportion of Participants as per Gender with NT1 and NT2 at Diagnosis
Time frame: Up to approximately 10 years
Core Group: Proportion of Participants as per Age with NT1 and NT2 at Diagnosis
Time frame: Up to approximately 10 years
Core Group: Proportion of Participants as per Gender with NT1 and NT2 at Symptom Onset
Time frame: Up to approximately 10 years
Core Group: Proportion of Participants as per Age with NT1 and NT2 at Symptom Onset
Time frame: Up to approximately 10 years
Core Group: Percentage Change in NT1 and NT2 Prevalence Over Past 10 Years
The overall prevalence will be calculated as the number of participants diagnosed with NT1 and NT2 from all public hospitals reporting cases divided by number of people living in the areas served by these hospitals resulting in prevalence fraction. The overall percentage change of participant resulting from the above method will be reported.
Time frame: Up to 10 years
Core Group: Percentage Change in Adult With NT1 and NT2 Prevalence Over Past 10 Years
The overall prevalence will be calculated as the number of adult participants diagnosed with NT1 and NT2 from all public hospitals reporting cases divided by number of adult people living in the areas served by these hospitals resulting in a study prevalence fraction. The overall percentage change of participant resulting from the above method will be reported.
Time frame: Up to 10 years
Core Group: Percentage Change in Paediatric/Adolescent NT1 and NT2 Prevalence Over Past 10 Years
The overall prevalence will be calculated as the number of paediatric/adolescent participants diagnosed with NT1 and NT2 from all public hospitals reporting cases divided by number of paediatric/adolescent living in the areas served by these hospitals resulting in a study prevalence fraction. The overall percentage of participant resulting from the above method will be reported.
Time frame: Up to 10 years
Core Group: Percentage Change in NT1 and NT2 Incidence Over Past 10 Years
The incidence will be calculated as number of participants diagnosed for the first time from all hospitals divided by number of people living in the areas served by these hospitals resulting in a study incidence fraction. The overall percentage change of participant resulting from the above method will be reported.
Time frame: Up to 10 years
Core Group: Percentage Change in Adult NT1 and NT2 Incidence Over Past 10 Years
The incidence will be calculated as number of adult participants diagnosed for the first time from all hospitals divided by number of adults living in the areas served by these hospitals resulting in a study incidence fraction. The overall percentage change of participant resulting from the above method will be reported.
Time frame: Up to 10 years
Core Group: Percentage Change in Paediatric/Adolescent NT1 and NT2 Incidence Over Past 10 Years
The incidence will be calculated as number of paediatric/adolescent participants diagnosed for the first time from all hospitals divided by number of paediatric/adolescent living in the areas served by these hospitals resulting in a study incidence fraction. The overall percentage of participant resulting from the above method will be reported.
Time frame: Up to 10 years
Core Group: Diagnostic Delay for Incident Participants with NT1 and NT2
Diagnostic delay means that cases that began to present symptoms in the years prior to one year and have not yet been diagnosed.
Time frame: Up to approximately 10 years
Core Group: Diagnostic Delay for Incident Adult Participants with NT1 and NT2
Diagnostic delay means that cases that began to present symptoms in the years prior to one year and have not yet been diagnosed.
Time frame: Up to approximately 10 years
Core Group: Diagnostic Delay for Incident Paediatric/Adolescent Participants with NT1 and NT2
Diagnostic delay means that cases that began to present symptoms in the years prior to one year and have not yet been diagnosed.
Time frame: Up to approximately 10 years
Core Group: Diagnostic Delay for Incident Male Participants with NT1 and NT2
Diagnostic delay means that cases that began to present symptoms in the years prior to one year and have not yet been diagnosed.
Time frame: Up to approximately 10 years
Core Group: Diagnostic Delay for Incident Female Participants with NT1 and NT2
Diagnostic delay means that cases that began to present symptoms in the years prior to one year and have not yet been diagnosed.
Time frame: Up to approximately 10 years
Core Group: Percentage Change in Diagnostic Delay for Participants With NT1 and NT2 Over Past 10 Years
Time frame: Up to 10 years
Core Group: Percentage Change in Diagnostic Delay for Adult Participants With NT1 and NT2 Over Past 10 Years
Time frame: Up to 10 years
Core Group: Percentage Change in Diagnostic Delay for Paediatric/Adolescent Participants With NT1 and NT2 Over Past 10 Years
Time frame: Up to 10 years
Core Group: Percentage Change in Diagnostic Delay for Male Participants With NT1 and NT2 Over Past 10 Years
Time frame: Up to 10 years
Core Group: Percentage Change in Diagnostic Delay for Female Participants With NT1 and NT2 Over Past 10 Years
Time frame: Up to 10 years
Supplementary Group: Proportion of Participants With NT1 and NT2 who Were Diagnosed at Public hospitals and Private Practices
Time frame: On a day of survey (any 1 day) during the study for each participant
Supplementary Group: Proportion of Participants who Choose to be Followed in Public, Private, or Both Types of Hospitals and Reasons
Time frame: On a day of survey (any 1 day) during the study for each participant
Supplementary Study: Age at symptom onset
Time frame: On a day of survey (any 1 day) during the study for each participant
Supplementary Study: Age at diagnosis
Time frame: On a day of survey (any 1 day) during the study for each participant
Supplementary Study: Proportion of Participants as per Speciality of the Doctor Visited First for Narcolepsy Symptoms
Time frame: On a day of survey (any 1 day) during the study for each participant
Supplementary Study: Proportion of Participants as per Speciality of the Doctor who Diagnosed Narcolepsy
Time frame: On a day of survey (any 1 day) during the study for each participant
Supplementary Study: Number of Doctors Visited by Participant Prior to Receiving a Narcolepsy Diagnosis
Time frame: On a day of survey (any 1 day) during the study for each participant
Supplementary Study: Proportion of Participants With Misdiagnosis Prior to Narcolepsy Diagnosis
Time frame: On a day of survey (any 1 day) during the study for each participant
Supplementary Study: Proportion of Participants with Comorbidities
Time frame: On a day of survey (any 1 day) during the study for each participant
Supplementary Study: Proportion of Participants as per Place of Residence (Autonomous Community)
Time frame: On a day of survey (any 1 day) during the study for each participant